Join Andrew Scott, author of "The Longevity Imperative," and Vijay Pande, founding general partner of a16z Bio + Health, as they challenge the conventional views on aging. They discuss the urgent need to shift from "sick care" to proactive health management, highlighting economic implications as life expectancy rises. Explore the complexities of personalized health, the importance of dismantling ageism, and how societal perceptions of aging must evolve. Reimagine a future where longevity means more than just surviving—it's about thriving at every age.

Vijay Pande, a founding general partner at a16z Bio + Health, and Julie Yoo, a fellow general partner at the same firm, explore the transformative challenges of integrating AI into healthcare. They discuss the potential of AI to streamline workflows, enhance doctor-patient interactions, and revolutionize clinical trials. The conversation touches on using AI for patient triage in emergency care and the shift towards value-based care, emphasizing the need for specialized AI models to interpret complex medical data while overcoming systemic barriers.

Today’s episode is with Mark Cuban, founder of multiple businesses, owner of the Dallas Mavericks, one of the sharks on Shark Tank, and cofounder of the Mark Cuban Cost Plus Drug Company. He is joined by Vijay Pande, founding partner of a16z Bio + Health. Together, they talk market forces in healthcare, the importance of trust to patients, and Mark’s ideas to tackle the Gordian knot that is American healthcare. Listen to our last two episodes on Healthcare x Fintech:When Two Giants Intersect: Healthcare Meets FintechHow Fintech is Reshaping Our $4T Healthcare Industry Stay Updated: Find a16z on Twitter: https://twitter.com/a16zFind a16z on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Vijay Pande and Julie Yoo from a16z Bio + Health discuss grand challenges in healthcare AI, including AI integration in healthcare workflows, value-based care, and innovation in clinical trials. They also share their thoughts on the AI startups they hope to see in the industry.

At the end of 2022, our team at a16z asked dozens of partners across the firm to spotlight one big idea that startups in their fields could tackle in 2023.Emerging from this exercise came 40+ builder-worthy pursuits for the year, ranging from entertainment franchise games to precision delivery of medicine to small modular reactors, and of course loads of AI applications.In our 2-part series, we’ll be covering 12 of these big ideas with the partners that shared them.Here in part 2, we’ll cover Fintech, American Dynamism, and Bio & Health. Listen in as we chat with Anish Acharya, Angela Strange, Michelle Volz, Ryan McEntush, Vijay Pande, and Julie Yoo.And for the full list of 40+ ideas, check out the full article: https://a16z.com/2022/12/15/big-ideas-in-tech-2023/Topics Covered:(0:59) GPT Unlocks Credit Counseling - Anish Acharya(9:53) Compliance as a Competitive Advantage - Angela Strange(23:31) Small Modular Reactors Advance the Nuclear Renaissance - Michelle Volz(33:48) Overhauling the Space Supply Chain - Ryan McEntush(44:40) The Biggest Company in the World - Vijay Pande(51:17) The Value-Based Care Stack - Julie YooResources:https://a16z.com/2022/11/02/america-space-age/https://a16z.com/2022/11/11/the-biggest-company-in-the-world/https://a16z.com/2021/01/08/the-new-tech-stack-for-virtual-first-care/ Stay Updated: Find us on Twitter: https://twitter.com/a16zFind us on LinkedIn: https://www.linkedin.com/company/a16zSubscribe on your favorite podcast app: https://a16z.simplecast.com/Follow our host: https://twitter.com/stephsmithioPlease note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. For more details please see a16z.com/disclosures.

Exploring the biotech revolution with Vijay Pande, discussing AI impact on drug development, challenges in biotech startups, healthcare transformation through software engineering, navigating regulatory landscapes, and the evolution of healthcare towards value-based care.

Dr. Vijay Pande and Daisy Wolf discuss AI's impact on healthcare, funding innovative companies, personalized medicine through tech, and the role of wearable devices. They explore revolutionizing healthcare with AI, optimizing health with mitochondrial supplements, and the future of mental health care. The podcast emphasizes the importance of leveraging technology for tailored and efficient healthcare delivery.

Over the last 20 years, the idea of “designing biology” has gone from science fiction to just science, as the field of synthetic biology has exploded, with applications from therapeutics to manufacturing and more. In this episode from January 2019, one of the pioneers in the field, professor James J. Collins of MIT, joins a16z general partner on the Bio + Health fund, Vijay Pande, and editorial partner Hanne Winarsky, to discuss the origins of synthetic biology or "synbio", to what "engineering and designing" biology really looks like in action and the disciplinary differences between how biologists and engineers see the world.

with @LauraDeming, @kpfortney, @vijaypande, and @omnivorousread Welcome to the first episode of Bio Eats World, a brand new podcast all about how biology is technology. Bio is breaking out of the lab and clinic and into our daily lives—on the verge of revolutionizing our world in ways we are only just beginning to imagine. In this episode, we talk all about the science of aging. Once a fringe field, aging research is now entering a new phase with the first clinical trials of aging-related drugs. As the entire field shifts into this moment of translation, what have we learned? What are the basic approaches to developing aging-related drugs? How is studying aging helping us understand diseases like cancer and Alzheimer's—and increasing the amount of time we are healthy—today?  In this conversation, Laura Deming, founder of The Longevity Fund; Kristen Fortney, co-founder of BioAge, a clinical-stage company focused on finding drugs to extend healthspan; Vijay Pande, general partner at a16z; and host Hanne Winarsky discuss the entire arc of aging science from one genetic tweak in a tiny worm to changing a whole paradigm of healthcare delivery.

Vijay Pande and Steph Smith discuss using DNA as data storage, comparing it to Moore's Law. They explore DNA's capacity, longevity, and potential for the future of biotech. The podcast covers advancements in DNA storage, challenges in DNA synthesis, and the efficiency of using DNA for data storage.